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Ferritin is a ubiquitous protein required for intracellular iron storage; its biosynthesis is mainly regulated by iron-regulatory proteins
(IRP1 and IRP2) at post-transcriptional level. This regulation prevents iron excess from promoting the formation of reactive oxygen
species (ROS). IRP1 is regulated by such factors as intracellular iron levels, the oxidants H2O2 and NO. We recently demonstrated that
oxalomalate (OMA, a-hydroxy-h-oxalosuccinic acid), a competitive inhibitor of aconitase, which is an enzyme of the citric acid cycle,
remarkably decreases the binding activity of IRP1. The aim of the present study was to investigate whether this molecule could affect the
expression of ferritin. The RNA-binding activity of IRP1, evaluated by gel retardation assay, decreased after treatment of several cell lines
with 5 mM OMA, with a maximal decrease of about 3-fold after 6 h. This effect remained almost constant up to 48 h after which it
returned to basal levels. Intracellular ferritin levels, determined by Western blot analysis, increased in correlation with the OMA-induced
decrease of IRP1 binding activity. Furthermore, treatment of cells with OMA caused a rise in ferritin mRNA levels. Interestingly, in cells
exposed to iron challenge, OMA-induced overexpression of ferritin prevented formation of ROS and cellular lipid peroxidation. These
data show that an inhibitor of aconitase, OMA, besides being involved in energetic metabolism, is able to control ferritin expression,
probably through molecular mechanisms of either post-transcriptional regulation or transcriptional modulation, with advantageous
consequences for the cell.
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1. Introduction (ROS) have been implicated in cancer and inflammationIron is an essential element for all living organisms. It is
required for many biological processes ranging from O2
transport to DNA synthesis and electron transport. Iron
accumulation in cells is potentially toxic because it promotes
oxidative injury. In fact, free iron catalyses a number of
reactions that generate oxygen free radicals via Fenton–
Haber Weiss chemistry and can lead to protein, DNA and
lipid damage [1]. Moreover, excess reactive oxygen species0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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di Salerno, Via Ponte Don Melillo, 84084, Fisciano (SA), Italy.[2,3]. To prevent the deleterious effects of iron, cells have
evolved homeostatic mechanisms that regulate transport,
storage and mobilization of cellular iron. Many proteins are
involved in iron metabolism [4]: ferritin, which concentrates
and detoxifies iron; the transferrin receptor and divalent metal
transporter (DMT-1), which are required for cellular iron
uptake, and ferroportin, which is required to remove iron
from the cell. Ferritin, the main iron storage protein, is
normally protective because it binds as many as 4500 atoms
of iron [5,6]. Expression of this protein, which is formed by
two types of subunits (H and L), is primarily regulated at
translational level by changes in iron availability, through
specifically regulated interactions between iron regulatory
proteins (IRP1 and IRP2) and iron-responsive elements (IRE)
contained within the 5V-untranslated region of H- and L-
ferritin mRNA. When cellular iron levels are low, IRP1
and/or IRP2 binds to the IRE cis-element in ferritin mRNA
and protein translation is blocked. When intracellular iron
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degraded and ferritin mRNA is efficiently translated (for
reviews, see Refs. [7–9]).
IRP1 is the cytosolic counterpart of [4Fe–4S] aconitase, a
key enzyme in the mitochondrial citric acid cycle [10,11]. It
is a bifunctional protein that, through [4Fe–4S] cluster
assembly/disassembly, switches from the aconitase form
(endowed with enzymatic activity), to the IRP1 form
(endowed with IRE-binding activity), in response to the
cellular iron level [12]. IRP1 activity is also regulated by
nitric oxide signaling [13,14], oxidative stress [15,16],
phosphorylation [17] and hypoxia [18,19]. We previously
reported that oxalomalate (OMA, a-hydroxy-h-oxalosuc-
cinic acid), a competitive inhibitor of aconitase [20,21],
remarkably decreased the RNA binding activity of the IRPs
[22]. OMA is produced in vitro by a non-enzymatic aldol
condensation between oxaloacetate with the highly reactive
glyoxylate [23,24]. Moreover, this reaction occurs also in
vivo by injecting animals with equimolar quantity of both
compounds [22] or could occur in mammalian cells under
physiological conditions when are present oxaloacetate and
glyoxylate, the latter being synthesized and catabolized also
in cells of vertebrate [25–27]. Considering that OMA
decreases the RNA binding activity of the IRPs in both
iron-repleted cells, which are rich in aconitase, and in iron-
depleted cells, which are rich in IRP1 and IRP2 [22], it is
feasible that this molecule, by specifically interacting with
aconitase/IRP1, prevents IRP– IRE binding on ferritin
mRNA thereby leading to increased ferritin translation. In
attempt to verify this hypothesis, we evaluated the levels of
ferritin in various cell types cultured with OMA and we
found that OMA increases intracellular ferritin content. In
addition, we observed an increase in ferritin mRNA levels
induced by OMA.We suppose that OMA could play a role in
controlling ferritin expression both at post-transcriptional
and at transcriptional level, leading to a major amount of
protein. Finally, the OMA-induced ferritin overexpression
decreases ROS formation and cellular lipid peroxidation,
thus protecting cells from iron-dependent oxidative injury.2. Experimental
2.1. Cell cultures and treatments
C6 rat glioma cells and 3T3-NIH mouse fibroblasts were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing high glucose (4.5 g/l), and supplemented with
10% fetal bovine serum, L-glutamine (2 mM), penicillin (50
units/ml) and streptomycin (50 Ag/ml). SH-SY5Y human
neuroblastoma cells were grown in Ham’s F12 nutrient
mixture/Eagle’s minimal essential medium (1:1) supple-
mented with 10% fetal bovine serum, 1% non-essential
amino acids, L-glutamine (1 mM), penicillin (50 units/ml)
and streptomycin (50 Ag/ml). Cells were cultured at 37 jC
in a humidified 5% CO2 atmosphere.Confluent cultures were incubated for different times at
37 jC with 5 mM OMA added to the medium containing 5%
fetal bovine serum. In cytoprotection experiments, cells were
treated with 2.5–40 Ag/ml of ferric ammonium citrate (FAC)
for 2 h at 37 jC. Cell viability was assessed by measuring the
level of mitochondrial dehydrogenase activity using 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) as the substrate [28]. Oxalomalic acid trisodium salt,
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide and FAC were purchased from Sigma (St. Louis,
MO, USA).
2.2. Preparation and treatment of cytosolic extracts
Cells were washed and scraped off with PBS containing 1
mM EDTA. To obtain cytoplasmic extracts, cells were lysed
with buffer containing 10 mM Hepes, pH 7.5, 3 mM MgCl2,
40 mM KCl, 5% glycerol, 1 mM dithiothreitol (DTT) and
0.2% Nonidet P-40 (NP-40) at 4 jC. Cell debris and nuclei
were pelleted by centrifugation at 13,000 rpm for 5 min at
4 jC and supernatants were stored at 80 jC. The protein
concentration was determined by the Bio-Rad protein assay,
according to the supplier’s manual (Bio-Rad Laboratories,
Milan, Italy). For in vitro experiments, cytosolic lysates (5
Ag) from cells were incubated for 10 min at room temper-
ature with OMA (2.5 and 5 mM), with Na-citrate (2.5 and 5
mM) and with cis-aconitate (2.5 and 5 mM).
2.3. Electrophoretic mobility-shift assay (EMSA)
Plasmid pSPT-fer, containing the sequence corresponding
to the IRE of the H-chain of human ferritin, linearized at the
BamHI site, was transcribed in vitro as we previously
described [29]. For band shift analysis, protein extracts (5
Ag) were incubated for 30 min at room temperature with 0.2
ng of in vitro transcribed 32P-labelled IRE RNA. The reaction
was performed in lysis buffer (10 mM Hepes, pH 7.5, 3 mM
MgCl2, 40 mMKCl, 5% glycerol, 1 mMDTTand 0.07%NP-
40) in a final volume of 20 Al. To recover total IRP1 binding
activity, cytosolic extracts were preincubated for 10 min with
2-mercaptoethanol (2-ME) at a 2% final concentration,
before the addition of 32P-labelled IRE RNA. Unbound
RNA was digested for 10 min with 1 unit of RNase T1
(Roche, Mannheim, Germany) and non-specific RNA–pro-
tein interaction was displaced by the addition of 5 mg/ml
heparin for 10 min. RNA–protein complexes were separated
on 6% non-denaturing polyacrylamide gel for 2 h at 200 V.
After electrophoresis, the gel was dried and autoradiographed
at 80 jC. The IRP–IRE complexes were quantified with a
GS-700 imaging densitometer and/or with GS-505 molecular
imager system (Bio-Rad).
2.4. Western blot analysis
For Western blot analysis, lysate aliquots containing
30–50 Ag of proteins were denatured, separated on a 12%
Fig. 1. Aconitase substrates and the RNA-binding activity of IRP1.
Cytoplasmic lysates (5 Ag) from confluent cultures of 3T3-NIH cells were
incubated in vitro for 10 min at room temperature with 2.5 and 5 mM OMA
(lanes 2 and 3), 2.5 and 5 mM citrate (lanes 5 and 6), 2.5 and 5 mM cis-
aconitate (lanes 8 and 9). Lanes 1, 4 and 7: untreated lysates. Subsequently,
the IRP–IRE binding activity was analyzed by gel mobility-shift assay
performed with an excess of 32P-labelled IRE probe on non-denaturing 6%
polyacrylamide gel.
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membrane (Amersham, Biosciences, UK) using a Bio-Rad
Transblot (Bio-Rad). Proteins were visualized on the filters
by reversible staining with Ponceau-S solution (Sigma) and
destained in PBS. Membranes were blocked at 4 jC in
milk buffer (1 PBS, 10% non-fat dry milk, 0.1% Triton
X-100) and then incubated for 3 h at room temperature
with sheep antibody to human ferritin (Biodesign Interna-
tional, Saco, ME, USA). Subsequently, the membranes
were incubated for 90 min at room temperature with
donkey peroxidase-conjugated anti-sheep IgG (Biodesign
International), and the resulting complexes were visualized
using chemoluminescence Western blotting detection
reagents (ECL, Supersignal West Pico, Pierce, Rockford,
IL, USA).
2.5. RNA extraction and Northern blot analysis
Total cellular RNAwas isolated from rat glioma cells (C6)
using the TRIzol reagent (Invitrogen, Life Technologies) as
indicated in the manufacturer’s instructions. For Northern
blots, 10 Ag of total RNA were fractionated on a 1.5%
agarose denaturing formaldehyde gel and then transferred
to Hybond-N filters (Amersham Biosciences). The hybrid-
ization was performed for 18 h at 65 jC in 0.5 M sodium
phosphate buffer pH 7.2, 1 mM EDTA pH 8.0, 7% (w/v)
SDS. The filters were washed in 0.05 M sodium phosphate
buffer pH 7.2, 1% (w/v) SDS at 65 jC and autoradiographed
at 80 jC. cDNA fragment corresponding to human cDNA
for H ferritin was 32P-radiolabelled using the random prim-
ing method (TaKaRa Biomedicals, Japan).
2.6. Measurement of ROS
The formation of ROS was evaluated by means of the
probe 2V,7V-dichlorofluorescin-diacetate (H2DCF-DA) as de-
scribed [30]. Briefly, C6 glioma cells were grown in DMEM
containing 10% (v/v) fetal bovine serum, thenwere plated at a
density of 5000 cells/well into 96-well dishes in medium
containing 5 mM OMA or without. Cells were allowed to
grow for 48 h and then incubated in the growth medium
containing 5 AM of H2DCF-DA (Sigma) for 1 h at 37 jC.
H2DCF-DA is a non-fluorescent permeant molecule that
passively diffuses into cells, where the acetates are cleaved
by intracellular esterases to form H2DCF and thereby traps it
within the cell. In the presence of intracellular ROS, H2DCF
is rapidly oxidized to the highly fluorescent 2V,7V-dichloro-
fluorescein (DCF). Cells were washed twice with PBS buffer
and were then treated with medium containing freshly pre-
pared FAC at a concentration ranging from 2.5 to 40 Ag/ml for
2 h. After treatment, cells were washed twice with PBS buffer
and plates were placed in a fluorescent microplate reader
(Perkin Elmer LS 55 Luminescence Spectrometer, Perkin-
Elmer Ltd., Beaconsfield, England). Fluorescence was mon-
itored using an excitation wavelength of 485 nm and an
emission wavelength of 538 nm. In each experiment, fluo-rescence increase was measured in three replicate cultures for
each concentration of FAC.
2.7. Lipid peroxidation assay
Lipid peroxidation products from cells were measured
by the thiobarbituric acid colorimetric assay [31]. Briefly,
cells were treated with 5 mM OMA for 48 h, washed with
1 PBS and incubated with 10–20 Ag/ml of FAC for 2
h at 37 jC. After incubation, cells were washed and
scraped in 1 PBS containing 0.5 mM EDTA and 1.13
mM butylated hydroxytoluene. Cells were lysed by means
of six cycles of freezing and thawing. To 1 ml of cellular
lysate were added 2 ml of 10% (w/v) trichloroacetic acid
and, after centrifugation at 3000 rpm for 10 min, 1.3 ml of
0.5% (w/v) thiobarbituric acid were added and the mixture
was heated at 80–100 jC for 30 min. After cooling,
malondialdehyde (MDA) formation was recorded (A530
nm and A550 nm) in a Perkin Elmer LS-5B spectrofluo-
rimeter and the results are presented as picomoles of
MDA/mg of cell protein determined by the Bio-Rad
protein assay. A standard curve of MDA was used to
quantify the MDA levels formed during the experiments.
Chemicals were supplied by Sigma.3. Results
3.1. Effect of aconitase natural substrates and OMA on
RNA-binding activity of IRP1
We previously demonstrated that OMA, a specific com-
petitive inhibitor of cytoplasmic and mitochondrial aconi-
tase [23], interferes with the RNA-binding activity of IRP1
[22]. When OMA interacts with the cytosolic aconitase, a
consistent amount of the bifunctional protein aconitase/
IRP1 is blocked in the enzymatic form and is therefore
not available for the RNA-binding function. Natural sub-
strates of aconitase interact directly with the labile iron of
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IRP1 by reducing agents [32] and inhibit the cluster
disassembly promoted by nitric oxide [33,34]. In this
context, we compared the effects exerted by OMA and by
the natural substrates of aconitase on the RNA-binding
ability of IRP1.
To this aim we evaluated by EMSA the amount of IRP1
available in cell lysates for RNA-binding in the presence of
citrate, cis-aconitate or OMA. Cytoplasmic extracts from
confluent cultures of 3T3-NIH cells were incubated for 10
min with 2.5 and 5 mM OMA, citrate and cis-aconitate,
respectively (Fig. 1). As expected, OMA decreased the
RNA-binding activity of IRP1 and the effect was greatestFig. 2. Effect of OMA on the IRE-binding activity of IRPs. (A) C6 cells were incu
refers to untreated C6 cells. (B) C6 cells were incubated with 5 mM OMA for 24,
OMA treatment was repeated 48 h after the first incubation (to maintain the OMA
without and with 2-ME. The IRP–IRE complexes were quantified by phosphor im
treated with 2% 2-ME (100% of IRP1 activity). Filled bars, without 2-ME; op
representative result is shown; the error bars indicate standard deviations.at a concentration of 5 mM (lane 3). On the contrary,
incubation of cell extracts with citrate (lanes 5 and 6) or
with cis-aconitate (lanes 8 and 9), did not affect IRP1 binding
activity. These results demonstrate that, unlike OMA, the
natural substrates did not prevent the switch from aconitase
activity to IRE binding function of IRP1 and suggest that
OMAmay impair the RNA binding ability of IRP1 through a
specific interaction with different sites of the protein besides
the Fe–S cluster.
We next monitored the inhibition of IRP1 binding
capacity in several cell lines in time course experiments.
Cells were exposed for different times to 5 mM OMA, after
which we evaluated the IRE-binding activity of the IRPs. Inbated with 5 mM OMA in growth medium for 3, 6, 12, 18 and 24 h; time 0
48, 72 and 96 h. Time 0: untreated C6 cells; 72* h and 96* h: cells in which
effect constant). The IRP–IRE binding was analyzed by EMSA performed
aging and expressed as a percentage of the value obtained in control (time 0)
en bars, with 2-ME. The experiments were performed five times and a
Fig. 3. OMA increases ferritin protein levels. (A) Human SH-SY5Y neuroblastoma cells, (B) rat glioma C6 cells and (C) mouse 3T3-NIH fibroblasts were
treated with 5 mM OMA for 24, 48 and 72 h. In the experiment at 72 h, fresh medium containing OMAwas added to cell cultures 48 h after the first incubation.
Equal amounts of cytoplasmic lysates containing 40 Ag of proteins were fractionated by 12% SDS-polyacrylamide gel and subjected to Western blot analysis
using 1:250 diluted ferritin antiserum. Ferritin protein was visualized by chemoluminescence Western blotting detection reagents. In 3T3-NIH cells there were
two bands, of which the fast migrating one corresponded to the H-subunit. The bands corresponding to ferritin protein were quantified by densitometry and the
results are plotted as arbitrary units. These data are typical of four independent experiments; the error bars indicate standard deviations.
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shows a typical one using rat glioma cells (C6 line). The
IRE-binding activity of IRP1 decreased after 3 h, with a
maximum decrease of about 3-fold after 6 h of OMA
exposure (see Fig. 2A), after which the IRE-binding activity
slightly increased until 48 h, at 72 h this activity of IRP1 had
returned to baseline levels (Fig. 2B). To maintain constant
IRP1 inactivation it was necessary to replace OMA with
fresh solution after 48 h (see Fig. 2B, 72* h and 96* h).
When the cell extracts were treated with the reducing agent
2-ME, which allows full expression of IRP1 binding activ-
ity, the level of the activatable IRP1 in OMA-treated cells
was invariably lower versus controls (see both panels of Fig.
2, lanes with 2-ME addition), probably because OMAFig. 4. OMA increases ferritin mRNA. Rat glioma C6 cells were treated with 5
electrophoresed on 1.5% agarose-formaldehyde gel and blotted onto Hybond-N f
radiolabelled, as probe. On the right is shown ethidium bromide-stained RNA gel
were quantified by densitometry and the results are plotted as arbitrary units. These
error bars indicate standard deviations.hampers the reduction of cysteine residues in the protein
active site. Furthermore, incubation with OMA increased
IRP2 binding activity. This finding suggests that there is a
balance between the activities of the two IRPs with a
possible compensatory mechanism.
3.2. OMA increases ferritin expression
Because OMA binding to the aconitase/IRP1 prevents
the bifunctional protein from binding the IRE sequence, we
investigated whether the OMA-induced inactivation of IRP1
elicits specific translational activation of endogenous ferritin
mRNA. To this aim we evaluated by Western blot analysis
intracellular ferritin level on lysates from human SH-SY5YmM OMA for 24, 48 and 72 h. Total RNA was isolated and 10 Ag were
ilter. The hybridization was performed using human H-ferritin cDNA 32P-
as control for RNA loading. The bands corresponding to H-ferritin mRNA
data represent typical results obtained of three independent experiments; the
Fig. 5. Ferritin OMA-induced reduces ROS production and protects cells
from lipid peroxidation. (A) Cells were plated at a density of 5000 cells/
well into 96-well microplates and cultured with 5 mM OMA. After 48 h
cells were loaded with 5 AM H2DCF-DA for 1 h, exposed to FAC (2.5–40
Ag/ml) for 2 h and ROS formation was measured as described in Section
2.6. Fluorescence increase was measured in three replicate cultures for each
test. Data are expressed as meansFS.E. of three independent experiments.
RFU, relative fluorescence units. (B) C6 cells were cultured in medium
supplemented or not with 5 mM OMA for 48 h at 37 jC and then exposed
to 10 and 20 Ag/ml FAC for 2 h. Cells were lysed and lipid peroxidation
was measured by the thiobarbituric acid colorimetric assay. The results are
expressed as picomoles of MDA produced/mg of cell protein. The data
represent results obtained in at least three independent experiments; the
error bars indicate standard deviations.
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NIH fibroblasts. As shown in Fig. 3, OMA significantly
increased ferritin levels in all cell lines analyzed, a maxi-
mum being reached at 48 h. In particular, in human SH-
SY5Y neuroblastoma cells (Fig. 3A) and in rat C6 glioma
cells (Fig. 3B) ferritin levels increased by about 2.8- and 2-
fold, respectively. In mouse 3T3-NIH fibroblasts (Fig. 3C)
we detected two bands, of which the fast migrating one
corresponded to the H-subunit [35]. In these cells the L- and
H-ferritin increased by about 2-fold, with the H/L ratio
being constant. In agreement with EMSA results, the
addition of fresh medium containing OMA at 48 h stabilized
ferritin overexpression until 72 h. These results are consis-
tent with our hypothesis that OMA-induced inactivation of
IRE-binding activity of IRP1 leads to an increased ferritin
mRNA translation.
3.3. OMA induces an increase of ferritin mRNA
Ferritin mRNA levels are modulated by intracellular iron
content and by several factors [36], therefore we analyzed the
effect of OMA on the amounts of ferritin mRNA. Total RNA
extracted from rat C6 glioma cells after OMA treatment for
24, 48 and 72 h, was analyzed by Northern blot using human
ferritin H-chain cDNA as probe. The results shown in Fig. 4
demonstrate a significant increase in mRNA levels of H-
ferritin at 48 and 72 h. Similar induction of ferritin mRNA
was also observed in 3T3-NIH mouse fibroblasts (data not
shown). This finding suggests that OMA may modulate both
ferritin transcription and translation. These modulations can
collaborate in the determination of final cellular ferritin
content; however, other types of post-transcriptional regula-
tion, such as the level of mRNA stability cannot be excluded.
3.4. Induction of ferritin by OMA protects cells from the
toxic effects of iron
To verify whether the increased intracellular levels of
ferritin induced by OMA are related to endogenous iron
sequestration that protects the cell from oxidative stress, we
analyzed in cells exposed to iron challenge the accumulation
of ROS, by means of the fluorescent dye H2DCF-DA, and in
conjunction, we analyzed lipid peroxidation by quantifying
thiobarbiturate-reactive materials, to evaluate cell membrane
injury. To measure ROS production, C6 cells were cultured
with 5 mM OMA for 48 h and then pre-loaded with H2DCF-
DA prior to exposure for 2 h to iron challenge. Oxidation of
intracellular H2DCF-DA by ROS produces the fluorescent
DCF. As shown in Fig. 5A, in the control cells, after the
exposure to low FAC concentration (2.5–5.0 Ag/ml), we
observed a significant increases in the value of DCF oxida-
tion; then at higher iron concentration (10–40 Ag/ml) a stable
maximum level of oxidation occurred. In the OMA-treated
cells the overexpression of ferritin caused a remarkable
decrease of ROS accumulation at all FAC concentrations
utilized.To evaluate lipid peroxidation, C6 cells were cultured with
5mMOMA for 48 h and then exposed for 2 h to iron overload
induced by 10 or 20 Ag/ml FAC. As shown in Fig. 5B, ferric
ions caused a considerable degree of iron concentration-
dependent lipid peroxidation. Pre-treatment with OMA re-
duced lipid peroxidation to about 50% at an iron concen-
tration of 10 Ag/ml. When the iron level was increased to 20
Ag/ml, the OMA-induced ferritin still counteracted lipoper-
oxidation albeit to a lesser degree.
We conclude that OMA increases the translation of
ferritin that, by virtue of its iron segregating property,
protects the cell from iron-oxidant injury.4. Discussion
Cellular ferritin has been long thought to serve as an iron
storage protein that protects cells from the toxic effect of
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pulsed to induce ferritin become highly resistant to oxidant-
mediated injury and to accumulation of endothelial lipid
peroxidation products [37]. Moreover, exogenous apoferri-
tin or hemin-induced ferritin remarkably decreases iron-
induced lipid peroxidation in 3T3-L1 mature adipocytes
[29].
Cellular iron homeostasis is largely coordinated by the
cytoplasmic RNA-binding proteins IRPs. The regulation of
IRP1 activity is closely linked to the regulatory mechanism
of assembly/disassembly of the Fe–S cluster. When the
cluster is disassembled, the protein is able to bind the IRE
thereby resulting in suppression of the translation of ferritin
mRNA. Besides by iron, IRP1 activity is modulated by
exposure to nitric oxide [13,14], to hypoxia/reoxygenation
[18,19] or to hydrogen peroxide [38]. We have recently
demonstrated that OMA, a competitive inhibitor of aconi-
tase, binds cytoplasmic aconitase and prevents its switch to
IRP1, with a consequent decrease in IRE-binding activity
[22]. In the present study we evaluated whether OMA also
interferes with the translation of ferritin mRNA transcripts
as a consequence of IRP1 inhibition, and we demonstrate
that OMA invariably leads to an increase of the intracel-
lular level of ferritin in various cell lines, although a
contribution through transcriptional regulation cannot be
excluded.
Since aconitase substrates can interact with the [4Fe–4S]
cluster of IRP1 and antagonize its conversion to the RNA-
binding form when treated with reductants [32], we first
compared the RNA binding activity of IRP1 analyzed in
presence of OMA or in presence of the enzyme natural
substrates. We found that IRP1 inhibition was greatest with
5 mM of OMA, whereas neither citrate nor cis-aconitate
altered the binding activity. This finding suggest that the
highly negative-charged OMA may interact with amino acid
residues from the active site cleft of the IRP1, such as
arginine and/or lysine, which have been shown to be
important in high-affinity IRE binding [39,40]. Moreover,
it is also possible that the active site cleft could be altered by
the OMA interaction so as to induce local conformational
changes, preventing access to IRE sequence that are nor-
mally accessible for binding.
The OMA-induced inhibition of RNA binding was
maximal after 6 h of treatment, and the inhibition remained
almost constant until 48 h, after which the IRE-binding
activity returned to baseline levels (see Fig. 2). Thus,
inhibition of IRP1 by OMA, observed in all cell lines
analyzed, was a transient phenomenon and this could be
due to the equilibrium between the competitive inhibitor and
the natural substrate in the bond with the active site of
aconitase/IRP1 [13,14]. In addition, OMA can slowly de-
carboxylate and lose a negative charge probably necessary
for the formation of the complex with the active site of the
protein [41]. It is noteworthy that in the cell lines used, most
of IRP1 is already active in IRE binding, since treatment
with 2-ME only results in a marginal further activation.Bearing in mind that in all extracts of OMA-treated cells the
recovery of IRP1 activity by 2-ME was always less than that
of samples without OMA, we can suppose the possibility
that OMA could also modulate the IRE-binding activity in
the fraction of cluster-less apo-IRP1. Interestingly, some
IRP2 binding activity was restored concomitant with IRP1
inhibition. One reason for the increased IRP2 activity could
be that the two IRPs sense iron by different mechanisms. In
fact, at high intracellular iron levels, the cluster is assembled
and IRP1-binding activity is abolished, whereas IRP2
undergoes proteolytic degradation [42]. Moreover, IRP2 is
more sensitive than IRP1 to slight oscillations in intracellu-
lar iron level [43]. The increased ferritin expression induced
by OMA observed by us could reduce the chelatable iron
pool, a condition that is sensed more promptly by IRP2 than
by IRP1 [43]. The consequence is that the proteolytic
machinery involved in controlling IRP2 levels is slowed
down and its RNA-binding activity is enhanced.
To assess whether ferritin translation is induced in
response to inhibition of IRP1 binding to the IRE
contained in ferritin mRNA, we measured the protein
levels in various cell lines undergoing prolonged treatment
with OMA (24–72 h). We found a significant rise, with a
maximum at 48 h, of ferritin in all cell lines examined, and
the H/L ratio was constant (see Fig. 3C). Prolonged
incubation (up to 72 h) of the cells with fresh OMA-
containing medium did not further increase ferritin levels,
probably because the number of ferritin mRNA molecules
may change in response to a specific need of iron segre-
gation or distribution in cells. Moreover, our results of
Northern blot analysis show an increase of H-ferritin
mRNA content after OMA treatment (see Fig. 4). This
finding suggests that the increased ferritin levels observed
could result from an OMA-induced post-transcriptional
modulation coupled with ferritin gene transcription, even
if it remains to be established whether this rise in ferritin
mRNA is regulated at transcriptional level or is due to
other types of post-transcriptional regulation activated by
OMA, such as an increased mRNA stability.
Finally, we also verified if the increased ferritin level
induced by OMA protects cells from iron-dependent oxida-
tive stress. To elicit oxidation, we utilized the catalytic
properties of iron in the form of ferric ions to produce, via
the Fenton reaction, an excess of endogenous formation of
oxidative radicals. The results of the experiments with rat
glioma C6 cells cultured with OMA and then exposed to
iron challenge (see Fig. 5) demonstrated that an increased
intracellular ferritin level affect the formation either of
intracellular ROS that of the iron-induced lipid peroxida-
tion. These results are consistent with the reduced formation
of ROS observed in stably transfected cells with ferritin
such as erythroid [44] or HeLa [45] cells that overexpressed
this protein.
In conclusion, in the intriguing mechanism of sensing
intracellular iron levels, OMA may serve either to form a
transitory complex with the aconitase/IRP1 protein or prob-
R. Santamaria et al. / Biochimica et Biophysica Acta 1691 (2004) 151–159158ably to modulate ferritin transcription, with advantageous
consequences for the cell’s response to oxidative stress.
Should this be the case, a new horizon as an antioxidant
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